INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are believed to originate in Cajal mesenchymal cells and are commonly found in the stomach and small intestine, accounting for 80-90% of cases1. Surgical intervention is the preferred treatment for patients with resectable GIST lesions. Pathological diagnosis and genetic testing are crucial for postoperative targeted therapy in GIST patients, as most of them have mutations in KIT and PDGFRA sites. The use of tyrosine kinase inhibitors (TKIs) has significantly improved survival rates2, 3. Liver metastases in gastrointestinal tumors are often associated with a poor prognosis, with the liver being the most common site of metastasis for GIST, and up to 20% of GIST patients are found to have liver metastases during follow-up4-6. It is important to note that new lesions appearing in the liver after GIST surgery can be easily misdiagnosed as tumor metastasis7. However, primary liver lesions should not be overlooked and require further attention.